Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stevanato Group S.p.A.STVN · Entity 3826 | Director | June 12, 2026 | June 26, 2026 |
| WEST PHARMACEUTICAL SERVICES INCWST · Entity 3201 | Sr. VP & CFO | June 08, 2018 | June 11, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stevanato Group S.p.A.
Report date June 12, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 26,991 |
Ending reported balance
After 2026-06-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-12 · Grant · Acquired 4,975 · Balance 28,484 F1: Represents ordinary shares granted as equity compensation in connection with the Reporting Person's service as director. Row 2 · 2026-06-15 · Sale · Disposed 1,493 · Balance 26,991 F2: Represents ordinary shares sold by the Reporting Person to cover tax obligations associated with the grant of ordinary shares. |
| Ordinary SharesSEC Table I · non-derivative | IndirectBy spouse and others | 31,589 |
Reported balance
Holding disclosure · report date 2026-06-12 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 31,589 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents ordinary shares granted as equity compensation in connection with the Reporting Person's service as director.
F2: Represents ordinary shares sold by the Reporting Person to cover tax obligations associated with the grant of ordinary shares.
WEST PHARMACEUTICAL SERVICES INC
Report date June 08, 2018 · Filed June 11, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 227,812.3342 |
Ending reported balance
After 2018-06-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-06-08 · Exercise / conversion · Acquired 75,662 · Balance 270,681.3342 Row 2 · 2018-06-08 · Sale · Disposed 42,869 · Balance 227,812.3342 F1: This transaction was executed in multiple trades at prices ranging from $95.76 USD to $96.34 USD; the price reported above reflects the weighted average sale price. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.34 · Expires 2020-03-22 | Direct | 0 |
Reported balance
After 2018-06-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-06-08 · Exercise / conversion · Disposed 75,662 · Balance 0 F2: This award vests in 4 equal annual installments beginning on 3/22/2011. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 1,046.4185 |
Reported balance
Holding disclosure · report date 2018-06-08 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,046.4185 |
| Common StockSEC Table I · non-derivative | IndirectBy Nonqualified Deferred Comp Plan | 17,060.5586 |
Reported balance
Holding disclosure · report date 2018-06-08 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 17,060.5586 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $95.76 USD to $96.34 USD; the price reported above reflects the weighted average sale price.
F2: This award vests in 4 equal annual installments beginning on 3/22/2011.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Zynerba Pharmaceuticals, Inc.
Report date October 10, 2023 · Filed October 11, 2023
Section 16 reporting ended · disclosed 2023-10-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-10-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-10-10 · Other · Disposed 27,954 · Balance 47,824 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation ("Parent") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer (the "Offer") for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the "Effective Time" with the Issuer surviving the merger). (continued in footnote 2) F2: (Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the "Cash Amount") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a "CVR") per Share (the "CVR Amount" and together with the Cash Amount, the "Merger Consideration"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment"). Row 2 · 2023-10-10 · Other · Disposed 47,824 · Balance 0 F3: This line item represents unvested restricted stock awards ("RSAs") held by the Reporting Person that were tendered pursuant to the Offer. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time and not validly tendered in the Offer was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.01 · Expires 2032-06-14 | Direct | 0 |
Reported balance
After 2023-10-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-10-10 · Disposition to issuer · Disposed 34,663 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5) F5: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.35 · Expires 2033-06-13 | Direct | 0 |
Reported balance
After 2023-10-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-10-10 · Disposition to issuer · Disposed 71,736 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5) F5: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation ("Parent") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer (the "Offer") for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the "Effective Time" with the Issuer surviving the merger). (continued in footnote 2)
F2: (Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the "Cash Amount") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a "CVR") per Share (the "CVR Amount" and together with the Cash Amount, the "Merger Consideration"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment").
F3: This line item represents unvested restricted stock awards ("RSAs") held by the Reporting Person that were tendered pursuant to the Offer. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time and not validly tendered in the Offer was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5)
F5: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 26, 2026 10:04 UTC | Stevanato Group S.p.A. STVN · Entity 3826 | SaleOrdinary Shares | 1,493 | $17.09 | $25,515.37 |
DisclosureSEC source: 0001193125-26-283783 · ownership.xml · nonDerivative · entry 2 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,991 F2 · shares: Represents ordinary shares sold by the Reporting Person to cover tax obligations associated with the grant of ordinary shares. Read SEC document |
| June 12, 2026 Filed Jun 26, 2026 10:04 UTC | Stevanato Group S.p.A. STVN · Entity 3826 | GrantOrdinary Shares | 4,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-283783 · ownership.xml · nonDerivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,484 F1 · shares: Represents ordinary shares granted as equity compensation in connection with the Reporting Person's service as director. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 14:07 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | Disposition to issuerStock Option (Right to Buy) · Derivative | 71,736 | Not disclosed Strike: $0.35 | Not disclosed |
DisclosureSEC source: 0001140361-23-047735 · form4.xml · derivative · entry 4 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,736 shares Expires 2033-06-13 F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5) F5 · price: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5) F5 · derivative.exercise_date: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 14:07 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | Disposition to issuerStock Option (Right to Buy) · Derivative | 34,663 | Not disclosed Strike: $1.01 | Not disclosed |
DisclosureSEC source: 0001140361-23-047735 · form4.xml · derivative · entry 3 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,663 shares Expires 2032-06-14 F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5) F5 · price: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per Share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per Share exercise price of such option and (ii) one CVR. (continued in footnote 5) F5 · derivative.exercise_date: (Continued from footnote 4) Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per Share exercise price greater than or equal to the Cash Amount, and less than $2.71, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, minus the per Share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 14:07 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | OtherCommon Stock | 47,824 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-047735 · form4.xml · nonDerivative · entry 2 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · shares: This line item represents unvested restricted stock awards ("RSAs") held by the Reporting Person that were tendered pursuant to the Offer. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time and not validly tendered in the Offer was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest. F3 · price: This line item represents unvested restricted stock awards ("RSAs") held by the Reporting Person that were tendered pursuant to the Offer. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSA that was outstanding immediately prior to the Effective Time and not validly tendered in the Offer was cancelled and converted into the right to receive the Merger Consideration, subject to withholding of applicable taxes and without interest. Read SEC document |
| October 10, 2023 Filed Oct 11, 2023 14:07 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | OtherCommon Stock | 27,954 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-23-047735 · form4.xml · nonDerivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,824 F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of August 14, 2023, by and among the Issuer, Harmony Biosciences Holdings, Inc., a Delaware corporation ("Parent") and Xylophone Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer (the "Offer") for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of October 10, 2023 (the "Effective Time" with the Issuer surviving the merger). (continued in footnote 2) F2 · price: (Continued from footnote 1) At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (a) $1.1059 per Share (the "Cash Amount") in cash, subject to any applicable withholding taxes and without interest, plus (b) one contingent value right (each, a "CVR") per Share (the "CVR Amount" and together with the Cash Amount, the "Merger Consideration"), which represents the right to receive up to approximately $2.5444 per Share in the form of one or more potential contingent payments, in cash, subject to any applicable withholding taxes and without interest, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment"). Read SEC document |
| June 14, 2023 Filed Jun 15, 2023 20:29 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | SaleCommon Stock | 115 | $0.35 | $40.03 |
DisclosureSEC source: 0001062993-23-013665 · form4.xml · nonDerivative · entry 2 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,778 F2 · shares: This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees and taxes in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:29 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 71,736 | $0.00 Strike: $0.35 | $0.00 |
DisclosureSEC source: 0001062993-23-013665 · form4.xml · derivative · entry 3 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,736 Underlying: Common Stock · 71,736 shares Expires 2033-06-13 F3 · derivative.exercise_date: The option vests in full upon the earlier of (i) June 13, 2024 or (ii) the day before the Company's 2024 annual meeting of stockholders. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 20:29 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantCommon Stock | 47,824 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-013665 · form4.xml · nonDerivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,893 F1 · shares: The restricted stock award vests in full upon the earlier of (i) June 13, 2024 or (ii) the day before the Company's 2024 annual meeting of stockholders. Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 01:52 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 34,663 | $0.00 Strike: $1.01 | $0.00 |
DisclosureSEC source: 0001062993-22-015041 · form4.xml · derivative · entry 3 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,663 Underlying: Common Stock · 34,663 shares Expires 2032-06-14 F3 · derivative.exercise_date: The option vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders. Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 01:52 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | SaleCommon Stock | 40 | $1.01 | $40.40 |
DisclosureSEC source: 0001062993-22-015041 · form4.xml · nonDerivative · entry 2 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,069 F2 · shares: This transaction represents shares required to be sold by the Reporting Person to satisfy certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| June 14, 2022 Filed Jun 17, 2022 01:52 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantCommon Stock | 23,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-015041 · form4.xml · nonDerivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,109 F1 · shares: The restricted stock award vests in full upon the earlier of (i) June 14, 2023 or (ii) the day before the Company's 2023 annual meeting of stockholders. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:27 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $4.44 | $0.00 |
DisclosureSEC source: 0001192482-21-000645 · edgar.xml · derivative · entry 2 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-08-03 F2 · derivative.exercise_date: The option vests in full upon the earlier of (i) August 3, 2022, or (ii) the day before the Company's 2022 annual meeting of stockholders. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 21:27 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000645 · edgar.xml · nonDerivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · shares: The restricted stock award vests in full upon the earlier of (i) August 3, 2022, or (ii) the day before the Company's 2022 annual meeting of stockholders. Read SEC document |
| June 10, 2020 Filed Jun 11, 2020 21:38 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.21 | $0.00 |
DisclosureSEC source: 0001192482-20-000469 · edgar.xml · derivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: The option vests upon the earlier of (i) June 10, 2021 and (ii) the day before the Company's 2021 annual meeting of stockholders. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 20:18 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001192482-19-000282 · edgar.xml · derivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: The option vests upon the earlier of (i) June 11, 2020, or (ii) the day before the 2020 annual meeting of stockholders of Zynerba Pharmaceuticals, Inc. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:24 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 1,334 | $5.16 Strike: $7.86 | $6,878.10 |
DisclosureSEC source: 0001192482-18-000455 · edgar.xml · derivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,334 Underlying: Common Stock · 1,334 shares Expires 2028-10-01 F1 · price: This option was issued to the reporting person pursuant to the Zynerba Pharmaceuticals, Inc. Non-Employee Director Compensation Policy in lieu of cash retainer of $6,875.00. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 19:13 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 1,103 | $6.24 Strike: $9.70 | $6,877.21 |
DisclosureSEC source: 0001192482-18-000330 · edgar.xml · derivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,103 Underlying: Common Stock · 1,103 shares Expires 2028-07-02 F1 · price: This option was issued to the reporting person pursuant to the Zynerba Pharmaceuticals, Inc. Non-Employee Director Compensation Policy in lieu of cash retainer of $6,875.00. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 14:01 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 75,662 | $0.00 Strike: $21.34 | $0.00 |
DisclosureSEC source: 0001562180-18-002940 · primarydocument.xml · derivative · entry 5 FEDERICI WILLIAM J · CIK 0001260426 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,662 shares Expires 2020-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 3/22/2011. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 14:01 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 42,869 | $96.09 | $4,119,282.21 |
DisclosureSEC source: 0001562180-18-002940 · primarydocument.xml · nonDerivative · entry 2 FEDERICI WILLIAM J · CIK 0001260426 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,812.3342 F1 · price: This transaction was executed in multiple trades at prices ranging from $95.76 USD to $96.34 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 14:01 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 75,662 | $21.34 | $1,614,627.08 |
DisclosureSEC source: 0001562180-18-002940 · primarydocument.xml · nonDerivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,681.3342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 06, 2018 Filed Jun 7, 2018 20:32 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $11.30 | $0.00 |
DisclosureSEC source: 0001192482-18-000276 · edgar.xml · derivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: The option vests upon the earlier of (i) June 6, 2019, or (ii) the day before the 2019 annual meeting of stockholders of Zynerba Pharmaceuticals, Inc. Read SEC document |
| May 09, 2018 Filed May 11, 2018 19:28 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 52,000 | $0.00 Strike: $16.05 | $0.00 |
DisclosureSEC source: 0001562180-18-002453 · primarydocument.xml · derivative · entry 5 FEDERICI WILLIAM J · CIK 0001260426 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,000 shares Expires 2019-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/24/2010. Read SEC document |
| May 09, 2018 Filed May 11, 2018 19:28 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 52,000 | $87.14 | $4,531,280.00 |
DisclosureSEC source: 0001562180-18-002453 · primarydocument.xml · nonDerivative · entry 2 FEDERICI WILLIAM J · CIK 0001260426 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,019.3342 F1 · price: This transaction was executed in multiple trades at prices ranging from $86.95 USD to $87.80 USD; the price reported above reflects the weighted average sale price. Read SEC document |
| May 09, 2018 Filed May 11, 2018 19:28 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 52,000 | $16.05 | $834,340.00 |
DisclosureSEC source: 0001562180-18-002453 · primarydocument.xml · nonDerivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,019.3342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 02, 2018 Filed Apr 3, 2018 20:15 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 1,344 | $5.11 Strike: $7.98 | $6,873.89 |
DisclosureSEC source: 0001192482-18-000148 · edgar.xml · derivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,344 Underlying: Common Stock · 1,344 shares Expires 2028-04-02 F1 · price: This option was issued to the reporting person pursuant to the Zynerba Pharmaceuticals, Inc. Non-Employee Director Compensation Policy in lieu of cash retainer of $6,875.00. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 22:36 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 17,544 | $89.64 Strike: $89.64 | $1,572,644.16 |
DisclosureSEC source: 0001562180-18-001149 · primarydocument.xml · derivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,544 Underlying: Common Stock · 17,544 shares Expires 2028-02-20 F1 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/20/2019 Read SEC document |
| February 13, 2018 Filed Feb 15, 2018 23:14 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 4,526 | $93.00 | $420,918.00 |
DisclosureSEC source: 0001562180-18-001011 · primarydocument.xml · nonDerivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,019.3342 F1 · shares: 2015 PSU (PP14) award vesting Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:06 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 754 | $8.29 Strike: $13.00 | $6,249.91 |
DisclosureSEC source: 0001192482-18-000006 · edgar.xml · derivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 754 Underlying: Common Stock · 754 shares Expires 2028-01-02 F1 · price: This option was issued to the reporting person pursuant to the Zynerba Pharmaceuticals, Inc. Non-Employee Director Compensation Policy in lieu of cash retainer of $6,250.00. Read SEC document |
| December 08, 2017 Filed Dec 12, 2017 22:02 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 21,000 | $99.01 | $2,079,210.00 |
DisclosureSEC source: 0001562180-17-003845 · primarydocument.xml · nonDerivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,493.3342 Read SEC document |
| November 09, 2017 Filed Feb 14, 2018 22:28 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GiftCommon Stock | 3,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-000946 · primarydocument.xml · nonDerivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,093.3342 Read SEC document |
| October 02, 2017 Filed Oct 3, 2017 20:05 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 1,714 | $5.47 Strike: $8.69 | $9,375.58 |
DisclosureSEC source: 0001123292-17-001492 · edgar.xml · derivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,714 Underlying: Common Stock · 1,714 shares Expires 2027-10-02 F1 · price: This option was issued to the reporting person pursuant to the Zynerba Pharmaceuticals, Inc. Non-Employee Director Compensation Policy in lieu of cash retainer of $9,375. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 20:00 UTC | Zynerba Pharmaceuticals, Inc. PHH · Entity 109058 | GrantStock Option (right to buy) · Derivative | 882 | $10.63 Strike: $16.90 | $9,375.66 |
DisclosureSEC source: 0001123292-17-001201 · edgar.xml · derivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 882 Underlying: Common Stock · 882 shares Expires 2027-07-03 F1 · price: This option was issued to the reporting person pursuant to the Zynerba Pharmaceuticals, Inc. Non-Employee Director Compensation Policy in lieu of cash retainer of $9,375. Read SEC document |
| June 07, 2017 Filed Jun 9, 2017 21:11 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $18.77 | $0.00 |
DisclosureSEC source: 0001123292-17-001120 · edgar.xml · derivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The option vests on the earlier of (i) June 7, 2018 and (ii) the day before the 2018 annual meeting of stockholders of Zynerba Pharmaceuticals, Inc. Read SEC document |
| May 18, 2017 Filed May 18, 2017 20:14 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionStock Options (Right to Buy) · Derivative | 54,996 | $20.85 Strike: $20.85 | $1,146,666.60 |
DisclosureSEC source: 0001562180-17-001995 · primarydocument.xml · derivative · entry 6 FEDERICI WILLIAM J · CIK 0001260426 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 54,996 shares Expires 2018-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 18, 2017 Filed May 18, 2017 20:14 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 2,600 | $96.00 | $249,611.96 |
DisclosureSEC source: 0001562180-17-001995 · primarydocument.xml · nonDerivative · entry 3 FEDERICI WILLIAM J · CIK 0001260426 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,493.3342 F3 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $96.00 to $96.07, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| May 18, 2017 Filed May 18, 2017 20:14 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | SaleCommon Stock | 52,396 | $95.42 | $4,999,484.85 |
DisclosureSEC source: 0001562180-17-001995 · primarydocument.xml · nonDerivative · entry 2 FEDERICI WILLIAM J · CIK 0001260426 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,093.3342 F2 · price: The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $95.00 to $95.99, inclusive. The reporting person undertakes to provide to West Pharmaceutical Services, Inc., any security holder of West Pharmaceutical Services, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range in this footnote. Read SEC document |
| May 18, 2017 Filed May 18, 2017 20:14 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | Exercise / conversionCommon Stock | 54,996 | $20.85 | $1,146,666.60 |
DisclosureSEC source: 0001562180-17-001995 · primarydocument.xml · nonDerivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,489.3342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 20:13 UTC | Zynerba Pharmaceuticals, Inc. ZYNE · Entity 109058 | GrantStock Option (right to buy) · Derivative | 734 | $12.77 Strike: $20.32 | $9,373.18 |
DisclosureSEC source: 0001123292-17-000802 · edgar.xml · derivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734 Underlying: Common Stock · 734 shares Expires 2027-04-03 F1 · price: This option was issued to the reporting person pursuant to the Zynerba Pharmaceuticals, Inc. Non-Employee Director Compensation Policy in lieu of cash retainer of $9,375. Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 20:18 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantStock Options (Right to buy) · Derivative | 19,512 | $83.47 Strike: $83.47 | $1,628,666.64 |
DisclosureSEC source: 0001562180-17-000848 · primarydocument.xml · derivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,512 Underlying: Common Stock · 19,512 shares Expires 2027-02-21 F1 · derivative.exercise_date: This award vests in 4 equal annual installments beginning on 2/21/2018. Read SEC document |
| February 14, 2017 Filed Feb 16, 2017 20:00 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GrantCommon Stock | 4,623 | $86.93 | $401,877.39 |
DisclosureSEC source: 0001562180-17-000734 · primarydocument.xml · nonDerivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,202.1252 F1 · shares: Shares represent the portion of the Performance Share Unit Award granted in 2014 that have vested for period 13. F2 · balance_after: Reflects additional shares purchased through dividend reinvestments based on most recent plan statement. Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 22:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GiftCommon Stock | 2,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-16-003811 · primarydocument.xml · nonDerivative · entry 2 FEDERICI WILLIAM J · CIK 0001260426 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,295.3325 Read SEC document |
| December 13, 2016 Filed Dec 15, 2016 22:38 UTC | WEST PHARMACEUTICAL SERVICES INC WST · Entity 3201 | GiftCommon Stock | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-16-003811 · primarydocument.xml · nonDerivative · entry 1 FEDERICI WILLIAM J · CIK 0001260426 · Sr. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,695.3325 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.